-
Guggenheim Starts Black Diamond Therapeutics (BDTX) at Buy
-
Black Diamond Therapeutics (BDTX) PT Lowered to $10 at H.C. Wainwright
-
Raymond James Resumes Black Diamond Therapeutics (BDTX) at Outperform
-
Black Diamond Therapeutics, Inc. (BDTX) Tops Q1 EPS by 93c
-
Stifel Reiterates Buy Rating on Black Diamond Therapeutics (BDTX)
-
Black Diamond Therapeutics (BDTX), Servier Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
-
Black Diamond Therapeutics (BDTX) PT Raised to $12 at H.C. Wainwright
-
Black Diamond Therapeutics (BDTX) PT Lowered to $15 at Stifel
-
Black Diamond Therapeutics, Inc. (BDTX) Tops Q4 EPS by 7c
-
NAYA Biosciences (NAYA) nominates new Board members
-
Black Diamond Therapeutics (BDTX) PT Lowered to $16 at Stifel
-
Black Diamond Therapeutics, Inc. (BDTX) Tops Q3 EPS by 9c
-
H.C. Wainwright Reiterates Buy Rating on Black Diamond Therapeutics (BDTX)
-
Piper Sandler Reiterates Overweight Rating on Black Diamond Therapeutics (BDTX)
-
Black Diamond Therapeutics (BDTX) Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
-
H.C. Wainwright Reiterates Buy Rating on Black Diamond Therapeutics (BDTX)
-
TD Cowen Reiterates Buy Rating on Black Diamond Therapeutics (BDTX)
-
Black Diamond (BDTX) Climbs 42% Following Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC
-
Black Diamond Therapeutics (BDTX) Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC
-
H.C. Wainwright Reiterates Buy Rating on Black Diamond Therapeutics (BDTX)
-
Piper Sandler Reiterates Overweight Rating on Black Diamond Therapeutics (BDTX)
-
Piper Sandler Reiterates Overweight Rating on Black Diamond Therapeutics (BDTX)
-
Gyre Therapeutics (GYRE) Appoints David M. Epstein to its Board
-
Black Diamond Therapeutics, Inc. (BDTX) Tops Q2 EPS by 3c
-
Piper Sandler Reiterates Overweight Rating on Black Diamond Therapeutics (BDTX)
-
Piper Sandler Reiterates Overweight Rating on Black Diamond Therapeutics (BDTX)

